Guizhou University Medical College, Guiyang 550025, Guizhou Province, China.
Department of Neurosurgery, Guizhou Provincial People's Hospital, Guiyang, China.
Int Immunopharmacol. 2024 Aug 20;137:112420. doi: 10.1016/j.intimp.2024.112420. Epub 2024 Jun 8.
This study aimed to explore the underlying mechanisms of sepsis and acute kidney injury (AKI), including sepsis-associated AKI (SA-AKI), a frequent complication in critically ill sepsis patients.
GWAS data was analyzed for genetic association between AKI and sepsis. Then, we systematically applied three distinct machine learning algorithms (LASSO, SVM-RFE, RF) to rigorously identify and validate signature genes of SA-AKI, assessing their diagnostic and prognostic value through ROC curves and survival analysis. The study also examined the functional and immunological aspects of these genes, potential drug targets, and ceRNA networks. A mouse model of sepsis was created to test the reliability of these signature genes.
LDSC confirmed a positive genetic correlation between AKI and sepsis, although no significant shared loci were found. Bidirectional MR analysis indicated mutual increased risks of AKI and sepsis. Then, 311 key genes common to sepsis and AKI were identified, with 42 significantly linked to sepsis prognosis. Six genes, selected through LASSO, SVM-RFE, and RF algorithms, showed excellent predictive performance for sepsis, AKI, and SA-AKI. The models demonstrated near-perfect AUCs in both training and testing datasets, and a perfect AUC in a sepsis mouse model. Significant differences in immune cells, immune-related pathways, HLA, and checkpoint genes were found between high- and low-risk groups. The study identified 62 potential drug treatments for sepsis and AKI and constructed a ceRNA network.
The identified signature genes hold potential clinical applications, including prognostic evaluation and targeted therapeutic strategies for sepsis and AKI. However, further research is needed to confirm these findings.
本研究旨在探讨脓毒症和急性肾损伤(AKI)的潜在机制,包括脓毒症相关 AKI(SA-AKI),这是危重症脓毒症患者的常见并发症。
对 AKI 与脓毒症的全基因组关联研究(GWAS)数据进行分析,以确定其遗传相关性。然后,我们系统地应用三种不同的机器学习算法(LASSO、SVM-RFE、RF),严格识别和验证 SA-AKI 的特征基因,通过 ROC 曲线和生存分析评估其诊断和预后价值。本研究还研究了这些基因的功能和免疫学方面、潜在的药物靶点和 ceRNA 网络。建立脓毒症小鼠模型,以验证这些特征基因的可靠性。
LD 检验证实 AKI 和脓毒症之间存在正遗传相关性,尽管没有发现显著的共同位点。双向 MR 分析表明 AKI 和脓毒症之间存在相互增加的风险。然后,确定了 311 个与脓毒症和 AKI 共同的关键基因,其中 42 个与脓毒症预后显著相关。通过 LASSO、SVM-RFE 和 RF 算法选择的 6 个基因对脓毒症、AKI 和 SA-AKI 的预测性能均表现出色。模型在训练和测试数据集以及脓毒症小鼠模型中均表现出近乎完美的 AUC。在高风险和低风险组之间,发现免疫细胞、免疫相关通路、HLA 和检查点基因存在显著差异。本研究确定了 62 种潜在的脓毒症和 AKI 药物治疗方法,并构建了 ceRNA 网络。
所确定的特征基因具有潜在的临床应用价值,包括对脓毒症和 AKI 的预后评估和靶向治疗策略。然而,需要进一步的研究来验证这些发现。